Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics


Salarius Pharmaceuticals Inc (SLRX): $1.84

0.01 (+0.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SLRX Stock Price Chart Interactive Chart >

Price chart for SLRX

SLRX Price/Volume Stats

Current price $1.84 52-week high $16.75
Prev. close $1.83 52-week low $1.70
Day low $1.80 Volume 23,800
Day high $1.85 Avg. volume 32,506
50-day MA $3.13 Dividend yield N/A
200-day MA $5.66 Market Cap 4.19M

Salarius Pharmaceuticals Inc (SLRX) Company Bio


Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.


SLRX Latest News Stream


Event/Time News Detail
Loading, please wait...

SLRX Latest Social Stream


Loading social stream, please wait...

View Full SLRX Social Stream

Latest SLRX News From Around the Web

Below are the latest news stories about SALARIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SLRX as an investment opportunity.

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and nine months ended September 30, 2022 and provided a business update. Highlights of the third quarter of 2022 and recent weeks include: Financial Highlights Cash and cash equivalents were $16.8

Yahoo | November 10, 2022

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abstracts related to the company’s compounds have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans and virtua

Yahoo | November 3, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of Hematology annual meeting later this year HOUSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today annou

Yahoo | October 27, 2022

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston. Dr. Santiesteban

Yahoo | October 19, 2022

Akouos, AVEO lead healthcare gainers; Salarius, RVL among losers

Akouos AKUS +86%. AVEO Pharmaceuticals AVEO +40%. Salarius Pharmaceuticals (SLRX) -25%. RVL Pharmaceuticals (RVLP) -13%

Seeking Alpha | October 18, 2022

Read More 'SLRX' Stories Here

SLRX Price Returns

1-mo -6.12%
3-mo -63.26%
6-mo -65.77%
1-year -87.83%
3-year -98.16%
5-year -99.92%
YTD -85.15%
2021 -45.54%
2020 -75.93%
2019 -54.18%
2018 -90.54%
2017 -33.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.831 seconds.